Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.

Abstract

BACKGROUND:

Previous studies have identified that patients with EGFR mutations tend to have better responses to targeted therapy, as well as chemotherapy; however, the effect of genetic alterations in terms of radiotherapy (RT)-related outcomes has not been fully assessed. We studied the impact of common non-small cell lung cancer (NSCLC) genetic alterations (EGFR, ALK and KRAS) in relation to objective response rate (ORR) to RT in patients with brain metastases.

METHODS:

From 2009-2015, 153 patients with an available genotyping status were treated with whole-brain irradiation (WBI) before receiving systemic therapy. Primary outcome was ORR; secondary outcomes included intracranial progression-free survival (IPFS) and overall survival (OS).

RESULTS:

Overall, ORR was 47.1%. ORR to RT varied significantly according to molecular status: EGFR (64.5%) ALK (54.5%) KRAS (20%) and WT (35.4%) (P = 0.001). EGFR mutation was the only independently associated factor for response to WBI (RR 3.52 [95% CI 1.6-7.7]; P = 0.002). Median IPFS was 10.8 months [95% CI 8.2-13.5] overall; however, IPFS also varied significantly according to molecular status: EGFR (18.2 months), ALK (18.4 months), KRAS (6.0 months) and WT (8.7 months) (P < 0.0001). OS for EGFR, ALK, KRAS and WT patients was 36.6, 32.2, 15.5 and 22.4 months, respectively (P = 0.014). Intracranial-ORR (HR 0.4 [95% CI 0.2-0.6], P < 0.001) and mutation status (HR 0.7 [95% CI 0.6-0.9], P < 0.042) were independently associated with a higher OS.

CONCLUSIONS:

RT response varies as per tumor molecular status. The presence of EGFR mutations favors the organ-specific response to RT, and is associated with longer OS in patients with NSCLC and BM.

KEY POINTS:

This study addressed for the first time the difference in radiotherapy-related outcomes in patients with different genotypes of non-small cell lung cancer (NSCLC) before they received systemic therapy. Results show that response to radiotherapy varies as per tumor molecular status, particularly EGFR-mutated tumors, have a favorable response to radiotherapy, contrary to KRAS-mutated tumors.

• Authors: Oscar Arrieta, Laura-Alejandra Ramírez-Tirado, Enrique Caballé-Perez, Alberto Mejia-Perez, Zyanya Lucia Zatarain-Barrón, Andrés F Cardona, Francisco Lozano-Ruíz, Manuel Segura-González, Graciela Cruz-Rico, Federico Maldonado, Rafael Rosell
• Journal: Thoracic cancer (Thorac Cancer) Vol. 11 Issue 4 Pg. 1026-1037 (04 2020) ISSN: 1759-7714 [Electronic] Singapore
• PMID: 32072746 (Publication Type: Journal Article)
• Copyright: © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Chemical References

• Biomarkers, Tumor
• KRAS protein, human
• ALK protein, human
• Anaplastic Lymphoma Kinase
• EGFR protein, human
• ErbB Receptors
• Proto-Oncogene Proteins p21(ras)

Topics

• Adenocarcinoma of Lung (genetics, mortality, pathology, radiotherapy)
• Aged
• Aged, 80 and over
• Anaplastic Lymphoma Kinase (genetics)
• Biomarkers, Tumor (genetics)
• Brain Neoplasms (genetics, mortality, radiotherapy, secondary)
• Carcinoma, Non-Small-Cell Lung (genetics, mortality, pathology, radiotherapy)
• ErbB Receptors (genetics)
• Female
• Follow-Up Studies
• Gene Expression Regulation, Neoplastic (radiation effects)
• Gene Rearrangement
• Humans
• Lung Neoplasms (genetics, mortality, pathology, radiotherapy)
• Male
• Middle Aged
• Mutation
• Prognosis
• Prospective Studies
• Proto-Oncogene Proteins p21(ras) (genetics)
• Radiotherapy (mortality)
• Survival Rate